Drug Report History #65191
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v3-FR | Version v1-EN | |
|---|---|---|
| Language (Changed) | Updated to: French | Was: English |
| Date Updated | 2018-10-22 | 2018-10-22 |
| Drug Identification Number (Changed) | Updated to: 02271931 | Was: 02374749 |
| Brand name (Changed) | Updated to: ACT ZOPICLONE | Was: ACT RIZATRIPTAN ODT |
| Common or Proper name (Changed) | Updated to: ZOPICLONE | Was: RIZATRIPTAN OD |
| Company Name (Changed) | Updated to: TEVA CANADA LIMITED | Was: ACTAVIS PHARMA COMPANY |
| Ingredients (Changed) | Updated to: ZOPICLONE | Was: RIZATRIPTAN |
| Strength(s) (Changed) | Updated to: 5MG | Was: 10MG |
| Dosage form(s) (Changed) | Updated to: TABLET | Was: TABLET (ORALLY DISINTEGRATING) |
| Route of administration | ORAL | ORAL |
| Packaging size (Changed) | Updated to: 100 | Was: 12 |
| Additional packaging sizes | ||
| ATC code (Changed) | Updated to: N05CF | Was: N02CC |
| ATC description (Changed) | Updated to: HYPNOTICS AND SEDATIVES | Was: ANTIMIGRAINE PREPARATIONS |
| Reason for discontinuation | Business reasons | Business reasons |
| Anticipated discontinuation date | ||
| Actual discontinuation date (Changed) | Updated to: 2018-04-30 | Was: 2018-03-30 |
| Remaining supply date (Changed) | Updated to: 2018-04-30 | Was: 2018-03-30 |
| Discontinuation status | Discontinued | Discontinued |
| Discontinuation decision reversal | no | no |
| Tier 3 Status | No | No |
| Information on remaining supply | ||
| Company comments | Transitioned. TEVA available | Transitioned. TEVA available |
| Health Canada comments |